Related Experiment Video
Updated: Jul 15, 2026
07:39
Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019
Expression of CD52 in peripheral T-cell lymphoma
Haematologica
|May 10, 2007
Summary
CD52 expression was evaluated in Peripheral T-cell lymphoma (PTCL/U), a rare cancer. Approximately 40% of PTCL/U cases showed CD52 expression, potentially guiding treatment selection for alemtuzumab therapy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Peripheral T-cell lymphoma unspecified (PTCL/U) presents a significant clinical challenge due to poor treatment outcomes and prognosis.
- CD52 is a cell surface protein targeted by the monoclonal antibody alemtuzumab.
- Understanding CD52 expression in PTCL/U is crucial for optimizing therapeutic strategies.
Discussion:
- This study investigated CD52 expression in PTCL/U using immunohistochemistry and gene expression analysis.
- CD52 protein expression was detected in approximately 40% of PTCL/U cases.
- The level of CD52 expression in PTCL/U was comparable to that observed in normal T-lymphocytes.
Key Insights:
- CD52 expression is present in a subset of PTCL/U, suggesting potential for targeted therapy.
- Immunohistochemistry and gene expression analysis are valuable tools for assessing CD52 levels in PTCL/U.
- The findings provide a basis for patient selection in alemtuzumab treatment protocols.
Outlook:
- Further research is warranted to elucidate the precise role of CD52 in PTCL/U pathogenesis and treatment response.
- Exploring combination therapies involving alemtuzumab could improve outcomes for PTCL/U patients.
- Biomarker-driven approaches, including CD52 assessment, are essential for personalized medicine in PTCL/U.
